New Hope for Blood Disorders: $32M Grant Funds Novel Therapy

PENNINGTON, N.J. and TOKYO – March 24, 2026 – A significant step has been taken in the fight against debilitating inherited blood disorders as biotechnology firm EpiFrontier Therapeutics secured up to $32 million in funding from the Japan Agency for Medical Research and Development (AMED). The grant is earmarked to advance a promising new drug, EPF-001, into mid-stage clinical trials, offering a new horizon of hope for millions suffering from sickle cell disease and beta thalassemia.

The non-dilutive funding—a crucial injection of capital that does not dilute ownership—validates the potential of EPF-001, a novel, first-in-class small molecule designed to tackle these diseases at a fundamental level. The move signals a major milestone for the young U.S.-based company, which is built upon a foundation of world-class Japanese scientific innovation.

A Persistent Global Health Crisis

Sickle cell disease (SCD) and beta thalassemia represent a group of genetic conditions known as beta globin disorders, which affect the structure or production of hemoglobin, the oxygen-carrying protein in red blood cells. Globally, these diseases impose a heavy burden, affecting millions of people and causing significant mortality, particularly in developing nations.

SCD, which affects an estimated 100,000 people in the United States and millions more worldwide, causes red blood cells to deform into a rigid "sickle" shape. These abnormal cells can block blood flow, leading to excruciating pain crises, chronic anemia, organ damage, stroke, and a life expectancy more than 20 years shorter than the general population.

Beta thalassemia, characterized by reduced production of hemoglobin, leads to severe anemia and a host of complications, including an enlarged spleen, bone deformities, and heart problems. Patients with the most severe form, transfusion-dependent thalassemia, are tethered to the healthcare system, requiring lifelong blood transfusions every two to four weeks. While life-saving, these transfusions lead to a dangerous buildup of iron in the body, necessitating a parallel, burdensome regimen of iron chelation therapy to prevent fatal organ damage.

While recent years have seen the landmark approval of curative gene therapies, these treatments are extraordinarily complex, astronomically expensive, and accessible to only a tiny fraction of patients at specialized medical centers. For the vast majority of patients, treatment remains focused on managing symptoms with older drugs like hydroxyurea or supportive care, leaving a significant unmet need for safer, more effective, and widely accessible therapies.

The Science of Reactivating a Fetal Switch

EpiFrontier’s EPF-001 represents a novel therapeutic strategy that aims to bypass the genetic defect rather than directly correct it. The drug is a highly selective inhibitor of G9a, an enzyme that plays a key role in silencing genes. In this case, the target is the gene responsible for producing fetal hemoglobin (HbF).

HbF is the primary oxygen carrier in a developing fetus but its production is largely switched off after birth, replaced by adult hemoglobin. The core idea behind EPF-001 is to inhibit G9a, effectively flipping the switch back on to reactivate HbF production in adults. Increased levels of healthy HbF can significantly improve the clinical picture for patients. In sickle cell disease, HbF interferes with the sickling process of red blood cells, while in beta thalassemia, it can compensate for the lack of functional adult hemoglobin, potentially reducing or eliminating the need for blood transfusions.

The development of EPF-001 is not a sudden breakthrough but the result of over a decade of meticulous research at two of Japan's most prestigious scientific institutions: RIKEN and the Tokyo University of Pharmacy and Life Sciences. The compound was identified after a comprehensive screening of approximately 140,000 molecules, followed by a sophisticated design process that involved synthesizing and evaluating over 1,000 derivative compounds to create a highly specific and potent candidate.

"We are honored to build upon the groundbreaking research conducted by our scientific founders," said Bruce Goldsmith, Chief Executive Officer of EpiFrontier Therapeutics. "Their innovative approach to targeting G9a has yielded a clinical candidate with the potential to meaningfully improve outcomes for patients suffering from beta globin disorders."

Japan's Strategic Investment in Global Innovation

The substantial grant from AMED is more than just financial support; it represents a key pillar of Japan's national strategy to become a global powerhouse in biotechnology. Through its "Strengthening Program for Pharmaceutical Startup Ecosystem," AMED aims to bridge the critical funding gap that often stalls the translation of brilliant academic science into life-changing medicines.

This program specifically supports startups developing innovative therapies that originate from Japanese research, contingent upon backing from certified venture capital firms like The University of Tokyo Edge Capital Partners (UTEC), which was an early investor in EpiFrontier.

Dr. Minoru Yoshida, Executive Vice President at RIKEN, highlighted the project's significance, stating, "The development of EPF-001 exemplifies RIKEN's commitment to translating fundamental scientific discoveries into therapies that address critical unmet medical needs... This partnership represents an important model for advancing Japanese innovation to benefit patients globally."

The structure of EpiFrontier itself—a U.S.-based corporation with a Japanese subsidiary, founded on Japanese science and backed by Japanese venture capital—embodies the cross-border collaboration model that AMED seeks to foster.

"EpiFrontier exemplifies the powerful combination of world-class Japanese science and global drug development expertise," noted Azusa Shiohara, Principal at UTEC and a Board Member of EpiFrontier. "We are proud to support this company as it brings this important Japanese innovation to patients worldwide."

The Path Forward: Clinical Trials and Commercialization

With the AMED funding secured, EpiFrontier Therapeutics is now poised to advance EPF-001 into Phase 2 clinical development. These crucial studies are designed to evaluate the drug's safety and efficacy in patients, providing the first "proof-of-concept" in humans.

The clinical trial program will be international in scope, targeting regions with large patient populations to ensure robust data collection. A specific arm of the study is planned for Japan, focusing on patients with severe beta thalassemia. This targeted approach will allow the company to gather essential data on the drug's potential to reduce transfusion burdens.

The company, which was founded in July 2025, has secured exclusive intellectual property rights from RIKEN and the Tokyo University of Pharmacy and Life Sciences. It is now focused on building a comprehensive patent portfolio to protect its innovation as it moves toward key commercialization milestones. If successful, EPF-001 could offer a transformative oral therapy that provides the benefits of increased fetal hemoglobin without the complexities and high costs associated with gene therapies, potentially changing the standard of care for millions of patients around the world.